As cancer survivorship improves, the number of patients with hematologic malignancies receiving palliative chemotherapy will grow. Older adults with hematologic malignancies often carry poor prognoses and experience high risks of infection. We evaluated the frequency of CDC criteria confirmed infection and antimicrobial use during hospitalizations following initiation of palliative chemotherapy.
Background: Gram--negative bacteremia in acute leukemia patients with neutropenia is associated with high morbidity and mortality rate. Appropriate antibiotic for empirical treatment is crucial; however, antibiotic selection is challenging especially in setting with high prevalence of infections with multidrug-resistant (MDR) organisms. Data on associated factors of MDR Gram-negative bacteremia in this population is limited.
Methods: A retrospective study was conducted in King Chulalongkorn Hospital, Bangkok, Thailand. Medical records of patients aged ≥15 years with acute leukemia who were hospitalized in our institute and had neutropenic fever between 1 January 2001 and 31 December 2016 were reviewed. Demographic data, causative organisms, treatment and outcomes were documented. Episodes of MDR Gram-negative bacteremia were compared with non-MDR group. Associated risk factor was assessed by multivariate logistic regression Results: From total 405 admission records of 227 acute leukemia patients, 587 episodes of neutropenic fever occurred with 131 episodes of Gram-negative bacteremia. Majority (81.68%) were bacteremia without source of infection. Most common causative pathogens were E. coli, P. aeruginosa and K. pneumoniae, respectively. Sixty episodes of Gram-negative bacteremia (53.57%) were caused by MDR pathogen. Associated factor for MDR Gram-negative bacteremia was prior colonization or infection with MDR Gram-negative bacteria within 3 months (P = 0.049). Subgroup analysis in patients with non-lactose fermenter bacteremia showed higher rate of intensive care unit (ICU) admission and in-hospital death in MDR group (P = 0.03 and P = 0.004).
Conclusion: Prior colonization or infection by MDR Gram-negative bacteria within 3 months was associated with MDR Gram-negative bacteremia in acute leukemia patients with neutropenic fever. Thoroughly review of previous culture data and active screening for colonization may increase chance of appropriate empirical antibiotics.
Disclosures. All authors:
No reported disclosures. Both SYK and JAK have knowmn critical roles in immunity against various pathogens. We aimed to determine the scope of infections in patients with lymphoid malignancies receiving Cerdulatinib therapy.
Infections in Patients Receiving Cerdulatinib for Treatment of Lymphoid Malignancies
Methods: Retrospective chart review of patients at Memorial Sloan Kettering Cancer Centers (MSKCC) who received at least 30 consecutive days of Cerdulatinib.
Infections were defined based on Infectious Diseases Society of America criteria and revised 2008 European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group guidelines. Serious infections were defined as infections requiring hospitalization and/or parenteral antimicrobial therapy.
Results: We identified 31 patients who received cerdulatinib at MSKCC. One patient was excluded due to receipt of less than 30 days of Cerdulatinib.In the 30 patients who were included mean age was 67 (range 23-80) years; 18 (58%) were men. All were receiving Pneumocystis jirovecii (PJP) prophylaxis with either TMP-SMX, Dapsone or Atovaquone and 17 patients (57%) were receiving Acyclovir or Valacyclovir prophylaxis. 8 patients (26%) developed serious infections during the follow-up period. These included two patients with invasive fungal infections, including one with invasive pulmonary aspergillosis and one with Scedosporidium endophtalmitis, one patient with cutaneous Mycobacterium avium infection, two patients with intraabdominal infections, one patient with disseminated Zoster (was not receiving antiviral prophylaxis), and two with influenza A infection one of which was complicated by bacterial pneumonia. All patients who developed infections were receiving Cerdulatinib monotherapy. Only one had been neutropenic or had received corticosteroids prior to development of infection.
Conclusion: Our data suggest that patients receiving Cerdulatinib therapy for lymphoid malignancies are at risk for serious infections, including invasive fungal infections.
Disclosures. All authors:
No reported disclosures. The PD-1 inhibitors or check point inhibitors (CPI) are commonly used for the treatment of many solid tumors (ST) and hematological malignancies (HM). By blocking PD-1 in fatigued T cells, an increase in viral clearance may be noted as evidenced in cases of JC virus. Our objective was to assess the outcomes related to cancer patients with microbiologically documented acute respiratory viral infections while on CPI.
Outcomes Related to Respiratory Viral Infections in Cancer Patients on PD-1 Inhibitors
Methods: All patients who were infected with either influenza, respiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (HMPV) from 9/2016 to 6/2018 with prior or concurrent CPI therapy were included in this study. Demographics and clinical data were collected retrospectively. Comparisons were done between patients with concurrent (group 1) or prior (group 2) CPI therapy.
Results: A total of 92 cancer patients were identified and of those, 50 patients (54%) were on concurrent CPI therapy at the time of infection. Most patients had ST, mainly non-small cell lung cancer, and most were predominantly infected with Influenza ( Figures  1 and 2) . Side effects-related to CPI therapy and steroid use prior to infection were uncommon (13%). When compared with group 2, patients in group 1 had a trend toward less lower respiratory tract infections (24% vs. 40%, P = 0.11), decreased median length of stay (3 vs. 8 days, P = 0.1125) and lower 30-day mortality (4% vs. 12%, P = 0.2396).
Conclusion: Our data demonstrated trends toward improved outcomes in patients with respiratory viral infections on concurrent CPI therapy. Whether improved outcomes are related to enhanced immune responses to these viral infections need to be determined in a larger prospective observational cohort of patients.
